Fibrin glue as a drug delivery system

Journal of Controlled Release

Volumn 148, Issue 1, 2010, Pages 49-55

  Spicer, Patrick P ^a   Mikos, Antonios G ^a  

^a Rice University   (United States)

Author keywords

Drug delivery; Fibrin glue; Gene delivery; Growth factor delivery; Tissue engineering

Indexed keywords

CELL DELIVERY; COVALENT LINKAGE; DRUG DELIVERY APPLICATIONS; DRUG DELIVERY SYSTEM; DRUG DELIVERY VEHICLES; FIBRIN GLUE; GENE DELIVERY; GROWTH FACTOR DELIVERY; MATRIX; RELEASE KINETICS;

CHEMOTHERAPY; DRUG DELIVERY; DRUG INTERACTIONS; GELS; GENE THERAPY; GENE TRANSFER; GLUES; GLUING; PEPTIDES; TISSUE;

TISSUE ENGINEERING;

(3 IODOBENZYL)GUANIDINE; ACIDIC FIBROBLAST GROWTH FACTOR; ADENOVIRUS VECTOR; ALGINIC ACID; APROTININ; BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN 2; DOXORUBICIN; ENOCITABINE; FIBRIN GLUE; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 1; FLUOROURACIL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MACROGOL; MITOMYCIN C; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SISOMICIN; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA1; VANCOMYCIN; VASCULOTROPIN 121; VASCULOTROPIN 165;

ARTICLE; CONTROLLED DRUG RELEASE; COVALENT BOND; CROSS LINKING; DACRON IMPLANT; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; MOLECULAR INTERACTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; DRUG DELIVERY SYSTEMS; FIBRIN TISSUE ADHESIVE; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649529351     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.025     Document Type: Article

References (56)

1. Antonelli M., Cicconetti F., Vivino G., Gasparetto A. Closure of a tracheoesophageal fistula by bronchoscopic application of fibrin glue and decontamination of the oral cavity. Chest 1991, 100:578-579.
2. Radosevich M., Goubran H.A. Burnouf, fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang. 1997, 72:133-143.
3. Flahiff C., Feldman D., Saltz R., Huang S. Mechanical-properties of fibrin adhesives for blood-vessel anastomosis. J. Biomed. Mater. Res. 1992, 26:481-491.
4. Jackson M.R., Friedman S.A., Carter A.J., Bayer V., Burge J.R., MacPhee M.J., Drohan W.N., Alving B.M. Hemostatic efficacy of a fibrin sealant-based topical agent in a femoral artery injury model: a randomized, blinded, placebo-controlled study. J. Vasc. Surg. 1997, 26:274-280.
5. Marx G., Mou X. Characterizing fibrin glue performance as modulated by heparin, aprotinin, and factor XIII. J. Lab. Clin. Med. 2002, 140:152-160.
6. Mouritzen C., Dromer M., Keinecke H.O. The effect of fibrin gluing to seal bronchial and alveolar leakages after pulmonary resections and decortications. Eur. J. Cardiothorac. Surg. 1993, 7:75-80.
7. Cox S., Cole M., Tawil B. Behavior of human dermal fibroblasts in three-dimensional fibrin clots: dependence on fibrinogen and thrombin concentration. Tissue Eng. 2004, 10:942-954.
8. Liu H., Collins S.F., Suggs L.J. Three-dimensional culture for expansion and differentiation of mouse embryonic stem cells. Biomaterials 2006, 27:6004-6014.
9. G. Zhang, C.T. Drinnan, L.R. Geuss, L.J. Suggs, Vascular differentiation of bone marrow stem cells is directed by a tunable three-dimension matrix, Acta Biomater. doi:10.1016/j.physletb.2003.10.071.
10. Mogford J.E., Tawil B., Jia S., Mustoe T.A. Fibrin sealant combined with fibroblasts and platelet-derived growth factor enhance wound healing in excisional wounds. Wound Repair Regen. 2009, 17:405-410.
11. Ho W., Tawil B., Dunn J.C.Y., Wu B.M. The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure. Tissue Eng. 2006, 12:1587-1595.
12. R. Mooney, B. Tawil, M. Mahoney, Specific Fibrinogen and Thrombin Concentrations Promote Neuronal Rather Than Glial Growth When Primary Neural Cells Are Seeded Within Plasma-Derived Fibrin Gels, Tissue Eng Part A (2010) 1607-1619.
13. Sierra D.H. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J. Biomater. Appl. 1993, 7:309.
14. Matras H. Fibrin seal: the state of the art. J. Oral Maxillofac. Surg. 1985, 43:605-611.
15. Beduschi R., Beduschi M.C., Wojno K.J., Jhung M., Williams A.L., Wolf J.S. Antifibrinolytic additives to fibrin glue for laparoscopic wound closure in urinary tract. J. Endourol. 1999, 13:283-287.
16. Pipan C.M., Glasheen W.P., Matthew T.L., Gonias S.L., Hwang L.J., Jane J.A., Spotnitz W.D. Effects of antifibrinolytic agents on the life span of fibrin sealant. J. Surg. Res. 1992, 53:402-407.
17. Sahni A., Francis C.W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000, 96:3772-3778.
18. Catelas I., Dwyer J.F., Helgerson S. Controlled release of bioactive transforming growth factor beta-1 from fibrin gels in vitro. Tissue Eng. Part C Methods 2008, 14:119-128.
19. Sahni A., Odrljin T., Francis C.W. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J. Biol. Chem. 1998, 273:7554-7559.
20. Campbell P.G., Durham S.K., Hayes J.D., Suwanichkul A., Powell D.R. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J. Biol. Chem. 1999, 274:30215-30221.
21. Huang M.C., Lo M.J., Lin Y.L., Chang S.E., Huang W.C., Kuo W.C., Tsai M.J., Kuo H.S., Shih Y.H., Cheng H. Functional recovery after the repair of transected cervical roots in the chronic stage of injury. J. Neurotrauma 2009, 26:1795-1804.
22. Wong C., Inman E., Spaethe R., Helgerson Fibrin-based biomaterials to deliver human growth factors. Thromb. Haemost. 2003, 89:573-582.
23. Becker J.C., Domschke W., Pohle T. Biological in vitro effects of fibrin glue: fibroblast proliferation, expression and binding of growth factors. Scand. J. Gastroenterol. 2004, 39:927-932.
24. C.T. Drinnan, G. Zhang, M.A. Alexander, A.S. Pulido, L.J. Suggs, Multimodal release of transforming growth factor-beta1 and the BB isoform of platelet derived growth factor from PEGylated fibrin gels, J. Control. Release. doi:10.1016/j.physletb.2003.10.071.
25. Huang Q., Goh J.C., Hutmacher D.W., Lee E.H. In vivo mesenchymal cell recruitment by a scaffold loaded with transforming growth factor beta1 and the potential for in situ chondrogenesis. Tissue Eng. 2002, 8:469-482.
26. Arkudas A., Tjiawi J., Saumweber A., Beier J.P., Polykandriotis E., Bleiziffer O., Horch R.E., Kneser U. Evaluation of blood vessel ingrowth in fibrin gel subject to type and concentration of growth factors. J. Cell. Mol. Med. 2008, 13:2864-2874.
27. Arkudas A., Pryymachuk G., Hoereth T., Beier J.P., Polykandriotis E., Bleiziffer O., Horch R.E., Kneser U. Dose-finding study of fibrin gel-immobilized vascular endothelial growth factor 165 and basic fibroblast growth factor in the arteriovenous loop rat model. Tissue Eng. A 2009, 15:2501-2511.
28. Catelas I., Sese N., Wu B.M., Dunn J.C.Y., Helgerson S., Tawil B. Human mesenchymal stem cell proliferation and osteogenic differentiation in fibrin gels in vitro. Tissue Eng. 2006, 12:2385-2396.
29. Gao C., Ma S., Ji Y., Wang J., Li J. Siatic nerve regeneration in rats stimulated by fibrin glue containing nerve growth factor: an experimental study. Injury 2008, 39:1414-1420.
30. Woodruff M.A., Rath S.N., Susanto E., Haupt L.M., Hutmacher D.W., Nurcombe V., Cool S.M. Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model. J. Mol. Histol. 2007, 38:425-433.
31. Levi A.D., Dancausse H., Li X., Duncan S., Horkey L., Oliviera M. Peripheral nerve grafts promoting central nervous system regeneration after spinal cord injury in the primate. J. Neurosurg. 2002, 96:197-205.
32. Cheng H., Hoffer B., Strömberg I., Russell D., Olson L. The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons. Exp. Brain Res. 1995, 104:199-206.
33. Schmökel H.G., Schense J.C., Weber F.E., Grätz K.W., Gnägi D., Müller R., Hubbell J.A. Bone healing in the rat and dog with nonglycosylated BMP-2 demonstrating low solubility in fibrin matrices. J. Orthop. Res. 2004, 22:376-381.
34. Schmökel H.G., Weber F.E., Seiler G., von Rechenberg B., Schense J.C., Schawalder P., Hubbell J. Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix. Vet. Surg. 2004, 33:112-118.
35. Erzurum V.Z., Bian J.F., Husak V.A., Ellinger J., Xue L., Burgess W.H., Greisler H.P. R136K fibroblast growth factor-1 mutant induces heparin-independent migration of endothelial cells through fibrin glue. J. Vasc. Surg. 2003, 37:1075-1081.
36. Shireman P.K., Xue L., Maddox E., Burgess W.H., Greisler H.P. The S130K fibroblast growth factor-1 mutant induces heparin-independent proliferation and is resistant to thrombin degradation in fibrin glue. J. Vasc. Surg. 2000, 31:382-390.
37. Patel V.V., Zhao L., Wong P., Pradhan B.B., Bae H.W., Kanim L., Delamarter R.B. An in vitro and in vivo analysis of fibrin glue use to control bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth. Spine J. 2006, 6:397-403. discussion 404.
38. Patel V.V., Zhao L., Wong P., Kanim L., Bae H.W., Pradhan B.B., Delamarter R.B. Controlling bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth using fibrin glue. Spine 2006, 31:1201-1206.
39. Zhibo X., Miaobo Z. Effect of sustained-release lidocaine on reduction of pain after subpectoral breast augmentation. Aesthet. Surg. J. 2009, 29:32-34.
40. Fujimoto K., Yamamura K., Osada T., Hayashi T., Nabeshima T., Matsushita M., Nishikimi N., Sakurai T., Nimura Y. Subcutaneous tissue distribution of vancomycin from a fibrin glue/Dacron graft carrier. J. Biomed. Mater. Res. 1997, 36:564-567.
41. Osada T., Yamamura K., Yano K., Fujimoto K., Mizuno K., Sakurai T., Nabeshima T. Distribution and serum concentration of sisomicin released from fibrin glue-sealed dacron graft in the rat and human. J. Biomed. Mater. Res. 2000, 52:53-57.
42. Yoshida H., Yamaoka Y., Shinoyama M., Kamiya A. Novel drug delivery system using autologous fibrin glue-release properties of anti-cancer drugs. Biol. Pharm. Bull. 2000, 23:371-374.
43. Kitazawa H., Sato H., Adachi I., Masuko Y., Horikoshi I. Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. Biol. Pharm. Bull. 1997, 20:278-281.
44. Yau L., Molnar P., Moon M.C., Buhay S., Werner J.P., Molnar K., Saward L., Del Rizzo D., Zahradka P. Meta-iodobenzylguanidine, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents neointimal hyperplasia. J. Pharmacol. Exp. Ther. 2008, 326:717-724.
45. Breen A., Dockery P., O'Brien T., Pandit A. Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. J. Biomed. Mater. Res. A 2009, 89:876-884.
46. Wan L., Li D., Wu Q. Perivenous application of fibrin glue as external support enhanced adventitial adenovirus transfection in rabbit model. J. Surg. Res. 2006, 135:312-316.
47. Teraishi F., Umeoka T., Saito T., Tsukagoshi T., Tanaka N., Fujiwara T. A novel method for gene delivery and expression in esophageal epithelium with fibrin glues containing replication-deficient adenovirus vector. Surg. Endosc. 2003, 17:1845-1848.
48. Arrighi I., Mark S., Alvisi M., von Rechenberg B., Hubbell J.A., Schense J.C. Bone healing induced by local delivery of an engineered parathyroid hormone prodrug. Biomaterials 2009, 30:1763-1771.
49. Morton T.J., Fürst W., van Griensven M., Redl H. Controlled release of substances bound to fibrin-anchors or of DNA. Drug Deliv. 2009, 16:102-107.
50. Schmökel H.G., Weber F.E., Schense J.C., Grätz K.W., Schawalder P., Hubbell J.A. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng. 2005, 89:253-262.
51. Willerth S.M., Rader A., Sakiyama-Elbert S.E. The effect of controlled growth factor delivery on embryonic stem cell differentiation inside fibrin scaffolds. Stem Cell Res. 2008, 1:205-218.
52. Wood M.D., Borschel G.H., Sakiyama-Elbert S.E. Controlled release of glial-derived neurotrophic factor from fibrin matrices containing an affinity-based delivery system. J. Biomed. Mater. Res. A 2009, 89:909-918.
53. Zhao W., Han Q., Lin H., Gao Y., Sun W., Zhao Y., Wang B., Chen B., Xiao Z., Dai J. Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin. J. Mol. Med. 2008, 86:1127-1138.
54. Zhao W., Han Q., Lin H., Sun W., Gao Y., Zhao Y., Wang B., Wang X., Chen B., Xiao Z., Dai J. Human basic fibroblast growth factor fused with Kringle4 peptide binds to a fibrin scaffold and enhances angiogenesis. Tissue Eng. A 2009, 15:991-998.
55. Zhang G., Nakamura Y., Wang X., Hu Q., Suggs L.J., Zhang J. Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart. Tissue Eng. 2007, 13:2063-2071.
56. Zhang G., Hu Q., Braunlin E.A., Suggs L.J., Zhang J. Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue Eng. A 2008, 14:1025-1036.